Market Overview:
The global next generation sequencing (NGS) market is expected to grow at a CAGR of 16.5% from 2018 to 2030. The growth in the market can be attributed to the increasing demand for NGS services from academic & government research institutes, pharmaceutical companies, biotechnology companies, and hospitals & clinics. Additionally, technological advancements in NGS platforms are also contributing to the growth of the market. However, high cost of NGS services is restraining the growth of this market. On the basis of type, targeted sequencing accounted for the largest share of the global NGS market in 2017. This segment is expected to grow at a CAGR of 17% during 2018-2030 owing to its ability to sequence specific regions or genes within a genome with high accuracy and speed as compared to other types of sequencing methods such as whole exome sequencing and whole genome sequencing. On account o fthe growing demand for personalized medicine across different applications such as cancer diagnosis and treatment,, targeted sequencing is gaining popularity among researchers and clinicians worldwide . On t he basis o f application , academic & government research institutes accounted for t he largest share o f th e global Next Generation Sequencing (NGS) Market i n 2017 .
 Industry Outlook.svg)
Product Definition:
Next generation sequencing (NGS) is a technology used to sequence DNA rapidly and cheaply. It has revolutionized the way scientists study DNA and genes, and has many applications in medical research, forensic science, and agriculture.
Targeted Sequencing:
Targeted sequencing is a process of identifying and analyzing specific regions of DNA. It helps in the identification of genetic markers that can be used for diagnosis, drug discovery, and research studies. The technology has been evolving over the past few years due to technological advancements such as gene targeting & genome engineering which have increased its application in diagnostics & therapeutics fields.
Whole Exome Sequencing:
Whole Exome Sequencing (WES) is a method that allows the sequencing of the complete human genome in one run. It includes data from all 19 locus or loci on each of the 22 chromosomes. The WES market has been growing at a rapid pace due to its increasing application in NGS-based diagnostics and therapeutics researchflows, which have further expanded with advent of new platforms for WES and associated services.
Application Insights:
The academic and government research institutes application segment led the market in 2017. This is attributed to the presence of a substantial number of researchers involved in genetic analysis studies at these institutes. Moreover, an increase in funding for NGS-based clinical trials by organizations such as the National Cancer Center, Japan has boosted industry growth.
Pharmaceutical companies are expected to emerge as one of the fastest-growing segments over the forecast period owing to factors such as an increase in drug discovery activities using NGS technology and rising incidences of diseases that can be diagnosed with precision owing to advanced diagnostics tools. The presence of a strong pipeline supporting product launches coupled with increasing R&D investments by pharmaceutical companies is anticipated to drive growth over the forecast period.
Regional Analysis:
North America dominated the global NGS market in terms of revenue share in 2017. This can be attributed to the presence of a substantial number of genetic disorders that require targeted sequencing for diagnosis, rising adoption of personalized medicine, and increasing investments by pharmaceutical companies. Moreover, growing initiatives by government organizations to increase awareness regarding genetic tests are expected to fuel the growth over the forecast period. For instance, in February 2018, New York State Department of Health launched a public awareness advertising campaign about NGS testing services offered through direct-to-consumer websites such as GeneDx and 23andMe Inc., along with new commercial entities called Genetic Clinics (See attached figure).
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to an increase in healthcare expenditure & development initiatives undertaken by governments across countries such as India & China for utilization next generation sequencing technologies at affordable prices.
Growth Factors:
- Increasing demand for personalized medicine: The global market for personalized medicine is expected to reach 0 billion by 2021. This is largely due to the increasing demand for targeted therapies and companion diagnostics. NGS is well-suited for personalizing treatments as it can identify genetic variants that may be associated with a particular disease.
- Advances in technology: The development of new sequencing technologies such as single molecule sequencing and nanopore sequencing has led to a decline in the cost of NGS data generation. This has made NGS more accessible to researchers and clinicians, driving its adoption in clinical settings.
- Growing interest in precision medicine: Precision medicine refers to the use of genomic information along with other patient data (e.g., lifestyle, environment) to tailor treatment decisions specifically for an individual patient. There is growing interest in precision medicine due to its potential benefits such as improved outcomes and reduced costs associated with treatment failures or adverse events caused by incorrect drug dosing etcetera .
- President Obama announced a 5 million investment towards precision Medicine Initiative (PMI).
Scope Of The Report
Report Attributes
Report Details
Report Title
Next Generation Sequencing (NGS) Market Research Report
By Type
Targeted Sequencing, Whole Exome Sequencing, Whole Genome Sequencing
By Application
Academic & Government Research Institutes, Pharmaceutical Companies, Biotechnology Companies, Hospitals & Clinics
By Companies
Illumina, Thermo Fisher Scientific, Pacific Biosciences of California, Beijing Genomics Institute, Qiagen, Roche, Agilent Technologies, Perkinelmer, Genomatix, PierianDx, Eurofins Scientific, Gatc Biotech, Oxford Nanopore Technologies, Bio-Rad Laboratories, DNASTAR, Biomatters, Partek, New England Biolabs, Myriad Genetics, Macrogen
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
232
Number of Tables & Figures
163
Customization Available
Yes, the report can be customized as per your need.
Global Next Generation Sequencing (NGS) Market Report Segments:
The global Next Generation Sequencing (NGS) market is segmented on the basis of:
Types
Targeted Sequencing, Whole Exome Sequencing, Whole Genome Sequencing
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Academic & Government Research Institutes, Pharmaceutical Companies, Biotechnology Companies, Hospitals & Clinics
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Illumina
- Thermo Fisher Scientific
- Pacific Biosciences of California
- Beijing Genomics Institute
- Qiagen
- Roche
- Agilent Technologies
- Perkinelmer
- Genomatix
- PierianDx
- Eurofins Scientific
- Gatc Biotech
- Oxford Nanopore Technologies
- Bio-Rad Laboratories
- DNASTAR
- Biomatters
- Partek
- New England Biolabs
- Myriad Genetics
- Macrogen
 Market Overview.svg)
Highlights of The Next Generation Sequencing (NGS) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Targeted Sequencing
- Whole Exome Sequencing
- Whole Genome Sequencing
- By Application:
- Academic & Government Research Institutes
- Pharmaceutical Companies
- Biotechnology Companies
- Hospitals & Clinics
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Next Generation Sequencing (NGS) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Next Generation Sequencing (NGS) is a technology that uses DNA sequencing to identify the sequence of nucleotides in a sample. NGS can be used to study large numbers of samples at once, making it an important tool for research and medical diagnosis.
Some of the key players operating in the next generation sequencing (ngs) market are Illumina, Thermo Fisher Scientific, Pacific Biosciences of California, Beijing Genomics Institute, Qiagen, Roche, Agilent Technologies, Perkinelmer, Genomatix, PierianDx, Eurofins Scientific, Gatc Biotech, Oxford Nanopore Technologies, Bio-Rad Laboratories, DNASTAR, Biomatters, Partek, New England Biolabs, Myriad Genetics, Macrogen.
The next generation sequencing (ngs) market is expected to grow at a compound annual growth rate of 16.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Next Generation Sequencing (NGS) Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Next Generation Sequencing (NGS) Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Next Generation Sequencing (NGS) Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Next Generation Sequencing (NGS) Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Next Generation Sequencing (NGS) Market Size & Forecast, 2018-2028
4.5.1 Next Generation Sequencing (NGS) Market Size and Y-o-Y Growth
4.5.2 Next Generation Sequencing (NGS) Market Absolute $ Opportunity
Chapter 5 Global Next Generation Sequencing (NGS) Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Next Generation Sequencing (NGS) Market Size Forecast by Type
5.2.1 Targeted Sequencing
5.2.2 Whole Exome Sequencing
5.2.3 Whole Genome Sequencing
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Next Generation Sequencing (NGS) Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Next Generation Sequencing (NGS) Market Size Forecast by Applications
6.2.1 Academic & Government Research Institutes
6.2.2 Pharmaceutical Companies
6.2.3 Biotechnology Companies
6.2.4 Hospitals & Clinics
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Next Generation Sequencing (NGS) Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Next Generation Sequencing (NGS) Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Next Generation Sequencing (NGS) Analysis and Forecast
9.1 Introduction
9.2 North America Next Generation Sequencing (NGS) Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Next Generation Sequencing (NGS) Market Size Forecast by Type
9.6.1 Targeted Sequencing
9.6.2 Whole Exome Sequencing
9.6.3 Whole Genome Sequencing
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Next Generation Sequencing (NGS) Market Size Forecast by Applications
9.10.1 Academic & Government Research Institutes
9.10.2 Pharmaceutical Companies
9.10.3 Biotechnology Companies
9.10.4 Hospitals & Clinics
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Next Generation Sequencing (NGS) Analysis and Forecast
10.1 Introduction
10.2 Europe Next Generation Sequencing (NGS) Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Next Generation Sequencing (NGS) Market Size Forecast by Type
10.6.1 Targeted Sequencing
10.6.2 Whole Exome Sequencing
10.6.3 Whole Genome Sequencing
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Next Generation Sequencing (NGS) Market Size Forecast by Applications
10.10.1 Academic & Government Research Institutes
10.10.2 Pharmaceutical Companies
10.10.3 Biotechnology Companies
10.10.4 Hospitals & Clinics
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Next Generation Sequencing (NGS) Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Next Generation Sequencing (NGS) Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Next Generation Sequencing (NGS) Market Size Forecast by Type
11.6.1 Targeted Sequencing
11.6.2 Whole Exome Sequencing
11.6.3 Whole Genome Sequencing
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Next Generation Sequencing (NGS) Market Size Forecast by Applications
11.10.1 Academic & Government Research Institutes
11.10.2 Pharmaceutical Companies
11.10.3 Biotechnology Companies
11.10.4 Hospitals & Clinics
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Next Generation Sequencing (NGS) Analysis and Forecast
12.1 Introduction
12.2 Latin America Next Generation Sequencing (NGS) Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Next Generation Sequencing (NGS) Market Size Forecast by Type
12.6.1 Targeted Sequencing
12.6.2 Whole Exome Sequencing
12.6.3 Whole Genome Sequencing
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Next Generation Sequencing (NGS) Market Size Forecast by Applications
12.10.1 Academic & Government Research Institutes
12.10.2 Pharmaceutical Companies
12.10.3 Biotechnology Companies
12.10.4 Hospitals & Clinics
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Next Generation Sequencing (NGS) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Next Generation Sequencing (NGS) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Next Generation Sequencing (NGS) Market Size Forecast by Type
13.6.1 Targeted Sequencing
13.6.2 Whole Exome Sequencing
13.6.3 Whole Genome Sequencing
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Next Generation Sequencing (NGS) Market Size Forecast by Applications
13.10.1 Academic & Government Research Institutes
13.10.2 Pharmaceutical Companies
13.10.3 Biotechnology Companies
13.10.4 Hospitals & Clinics
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Next Generation Sequencing (NGS) Market: Competitive Dashboard
14.2 Global Next Generation Sequencing (NGS) Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Illumina
14.3.2 Thermo Fisher Scientific
14.3.3 Pacific Biosciences of California
14.3.4 Beijing Genomics Institute
14.3.5 Qiagen
14.3.6 Roche
14.3.7 Agilent Technologies
14.3.8 Perkinelmer
14.3.9 Genomatix
14.3.10 PierianDx
14.3.11 Eurofins Scientific
14.3.12 Gatc Biotech
14.3.13 Oxford Nanopore Technologies
14.3.14 Bio-Rad Laboratories
14.3.15 DNASTAR
14.3.16 Biomatters
14.3.17 Partek
14.3.18 New England Biolabs
14.3.19 Myriad Genetics
14.3.20 Macrogen
